Can treatment with teicoplanin improve the prognosis of COVID‐19 patients?

Aim In patients with COVID‐19, no validated efficient treatment has been reported. Herein, we examine the effect of treatment with teicoplanin in hospitalised patients with COVID‐19. Methods This retrospective study included 115 hospitalised patients in one medical centre. Fifty‐four patients with l...

Full description

Saved in:
Bibliographic Details
Published in:International Journal of Clinical Practice 2021-11, Vol.75 (11), p.e14752-n/a
Main Authors: Yasar, Zehra, Yemisen, Mucahit, Yasar, Huseyin, Ertaş, Aysun, Meric, Kaan, Sahin, Soner
Format: Article
Language:English
Subjects:
clinical outcome
COVID-19
Medical prognosis
Mortality
mortality rate
Original Paper
Original Papers
Patients
Teicoplanin
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim In patients with COVID‐19, no validated efficient treatment has been reported. Herein, we examine the effect of treatment with teicoplanin in hospitalised patients with COVID‐19. Methods This retrospective study included 115 hospitalised patients in one medical centre. Fifty‐four patients with laboratory‐confirmed COVID‐19 who received teicoplanin plus standard care were included in the Teicoplanin arm of this study, whereas 61 patients who were treated with standard care (SC) according to the Turkish Health Organization guidelines were included in the control arm. Patients’ baseline characteristics, clinical presentation, treatment and outcomes were compared between the two groups. Results In this non‐randomised control study, all baseline characteristics were comparable between the two arms and there were no significant differences in the presenting symptoms, comorbidities and clinical outcomes between the two groups. However, the mortality rate was significantly lower in the teicoplanin group than in the control group (1.9% vs 14.8%; P 
ISSN:1368-5031
1742-1241
DOI:10.1111/ijcp.14752